Synapse Open Synapse
Biology

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Nature Medicine ·

Nature Medicine - Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Latest from Nature Medicine